Ignite Creation Date:
2024-05-06 @ 10:12 AM
Last Modification Date:
2024-10-26 @ 12:26 PM
Study NCT ID:
NCT03194633
Status:
COMPLETED
Last Update Posted:
2021-07-09
First Post:
2017-06-20
Brief Title:
Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients a Prospective Multicenter Observational Study
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients a Prospective Multicenter Observational Study
Status:
COMPLETED
Status Verified Date:
2021-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ADRENAL
Brief Summary:
Chronic kidney disease CKD and hypertension are two closely related common chronic diseases that have serious implications to human health Hypertension is a major cause for progression of renal disease and a risk factor for cardiovascular disease CVD Control of Blood Pressure BP to target is now considered to be the main goal in the treatment of patients with CKD
In clinical practice it is difficult for CKD patients with hypertension to achieve systolic BP SBP or diastolic BP DBP goal oftentimes calcium channel blocker CCB class of drugs for example nifedipine gastrointestinal therapeutic system GITS is used in such patients Previous data have demonstrated nifedipine to be having a significant dose-response relationship that is nifedipine 60 mg provided better BP reduction than 30 mg However there are limited studies that have evaluated the efficacy and tolerability of nifedipine GITS 60 mg in Chinese CKD patients with hypertension Hereby the objective of this study was to evaluate the effectiveness and tolerability of nifedipine GITS 60 mg treatment in a large cohort of CKD patients with uncontrolled hypertension
In clinical practice it is difficult for CKD patients with hypertension to achieve systolic BP SBP or diastolic BP DBP goal oftentimes calcium channel blocker CCB class of drugs for example nifedipine gastrointestinal therapeutic system GITS is used in such patients Previous data have demonstrated nifedipine to be having a significant dose-response relationship that is nifedipine 60 mg provided better BP reduction than 30 mg However there are limited studies that have evaluated the efficacy and tolerability of nifedipine GITS 60 mg in Chinese CKD patients with hypertension Hereby the objective of this study was to evaluate the effectiveness and tolerability of nifedipine GITS 60 mg treatment in a large cohort of CKD patients with uncontrolled hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None